Therapeutic synergy emerges from combined GPX4 inhibitor and PARP inhibitor treatment, which cooperatively induce ferroptosis in BRCA1-deficient ovarian cancer cells and potently inhibit tumor growth. This evidence concerns the gene PARP1 and ovarian carcinoma.